Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TAN-219
- Development stage
- Preclinical
- Lead developer
- Shanghai Thederma
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
TAN-219 is a small molecule aryl hydrocarbon receptor (AhR) modulator developed by Zedman Biopharma for the treatment of dry eye disease (keratoconjunctivitis sicca). Administered as an ophthalmic solution (eye drops), the drug targets the AhR pathway to potentially address ocular surface inflammation and restore homeostasis. As of 2024, the program is in the Investigational New Drug (IND) stage of development, representing one of Zedman Biopharma's early-stage pipeline assets in the ophthalmology space.
- Other names
- TAN-219 滴眼液TAN-219 Eye DropsTAN219 Eye DropsTAN 219 Eye Drops
02
Targets
AHR (Aryl hydrocarbon receptor)
Beyond the preview
Go deeper on TAN-219.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TAN-219.